Bothh Helicobacter pylori (HP) and Epstein-Barr virus (EBV)) have been implicated in carcinogenesis of the stomach.. Fifty-seven gastric carcinomas were tested forr microsatellite instability and allelic loss at several tumorr suppressor loci using 21 polymorphic microsatellitee markers. Furthermore, immunohistochemistryy for p53 and DPC4/SMAD4 was performed. Results weree analyzed according to HP and EBV status of the tumors,, as assessed by immunohistochemistry and RNAA in situ hybridization, respectively. Fractional allelicc loss was lower in EBV-positive carcinomas (M = 15)) when compared to EBV-negative carcinomas (P < 0.001).. EBV positivity was inversely associated with allelicc loss at specific markers on chromosomal arms 5qq C4PC), 17p (77*53), and 18q (DPC4/SMAD4). Allelic losss at the TP53 locus was not encountered in EBVpositivee carcinomas, but occurred in 51% of EBVnegativee carcinomas (P < 0.005). Moreover, none of thee EBV-positive carcinomas showed unequivocal p53 immunopositivityy in contrast to 39% of the EBV-negativee carcinomas (F < 0.01). EBV-status was not relatedd to microsatellite instability. There 'was no correlationn between HP-status and any of the molecular alterationss tested. In conclusion, EBV-positive gastric carcinomass follow a distinct pathogenesis at the molecularr level, in which p53 is not, or differently inactivated.. (Am J Pathol 2002 , 161:1207 -1213 Despitee its declining incidence in the western world, gastricc cancer remains one of the most frequent and lethal malignanciess worldwide. 1 The natural history of gastric cancerr is complex and incompletely understood but diet, infections,, and genetic factors are involved. More than 90%% of gastric cancers are adenocarcinomas, which can bee divided into two major histological types (intestinal andd diffuse) by the Lauren classification. 2 Off these two types, the tumorigenesis of the intestinal typee of gastric cancer is best understood It is thought to bee governed by environmental factors and is characterizedd by precursor lesions of the gastric mucosa.
] 3 These precursorr lesions are the morphological substrates of a stepwisee neoplastic process in which genetic changes havee accumulated gradually with tumor progression, similarr to the adenoma-carcinoma sequence in colorectal cancer.
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""' ' Infectiouss agents are important factors in carcinogenesiss of the stomach. Helicobacter pylori (HP) is a wellknownn risk factor and it is now considered a first class carcinogenn for stomach cancer.
67 Epstein-Barr virus (EBV)) is encountered in a subset of tumors but its role in gastricc carcinogenesis is less well understood. 8 The latencyy type in gastric carcinomas is different from the knownn EBV latency types as described for Burkitt's lymphomaa and nasopharyngeal carcinoma.
9 1D For example, thee latent membrane protein-1 (LMP-1) is not expressed inn EBV-positive stomach cancers. 10 Recent in vitro work byy Subramanian and colleagues 11 suggests that the EBV nuclearr protein EBNA-3C may functionally inactivate the humann metastatic suppressor protein Nm23-H1. Hypermethylationn of CpG islands as a mechanism of tumor suppressorr gene silencing in EBV carrying gastric cancerss has also been mentioned, 1^ and expression of RUNX3,RUNX3, a gene causally related to stomach cancer is inducedd by the EBV transcription factor EBNA-2.
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Inn the present study, using a variety of molecular markers,, we investigated gastric cancers for loss of heterozygosityy (LOH) at tumor suppressor loci known to be involvedd in carcinogenesis of the gastrointestinal tract 15 " 17 andd near tumor suppressor genes involved in syndromes thatt include gastric cancer in their phenotype. Furthermore,, the presence of microsatellite instability (MSI), a hallmarkk of a defective DNA mismatch repair system, was assessed.. The results of these analyses were evaluated withh respect to the HP and EBV status of the tumors to evaluatee the possible role of these infectious agents in carcinogenesiss of the stomach. 
MaterialsMaterials and Methods

PatientPatient Material
Formalin-fixed,, paraffin-embedded tissue of 57 gastric carcinomass was retrieved from the archives of the pathologyy departments of the Academic Medical Center (Amsterdam,, The Netherlands), the Lublin Medical Academy (Lublin,, Poland), and the Johns Hopkins Hospital (Baltimore,, MD). DNA was isolated from these tumors and polymerasee chain reaction (PCR) was performed using severall microsatellite primers as described below. Of thesee 57 gastric carcinomas the tumors consisted of 28 gastricc stump carcinomas (GSCs) and 29 gastric carcinomass of the intact stomach. The tumors were classified accordingg to the Lauren classification by an experienced gastrointestinall pathologist (GJAO). None of the tumors hadd a lymphoepithelioma-like histology. Patient and tumorr characteristics of the GSC and gastric carcinoma of thee intact stomach were comparable and not significantly different.. GSCs were used in this study because remote partiall gastrectomy is a premalignant condition that has ourr interest, 18 and EBV is relatively common in GSC.
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Thee prevalence of HP and EBV positivity was not significantlyy different in GSCs and gastric carcinoma of the intactt stomach in this series. Baseline characteristics accordingg to EBV status are summarized in Table 2 .
DetectionDetection of Epstein-Barr Virus and H. pylori
InIn situ hybridization for EBER1 nuclear RNA transcripts wass performed as previously described.' 9 HP status was assessedd initially by histopathological examination of the hematoxylinn and eosin-stained sections. Cases that were negativee for HP were subsequently tested by immunohistochemistryy using the B471 polyclonal rabbit anti-HP antibodyy (DAKO, Glostrup, Denmark), as described previously.
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MicrodissectionMicrodissection and DNA Isolation
Tumorr tissue was carefully microdissected from deparaffinizedd hematoxylin-stained 5-^m tissue sections. The percentagee of cancer cells had to be at least 50 to 60%. Forr each case, matching nontumorous tissue was obtainedd from either a tumor-free lymph node or, when this wass not available, from duodenum or smooth muscle cells.. The tissue was incubated overnight in 50 to 100 /xl off PK1 buffer (10 mmol/LTris, pH 8.3, 50 mmol/L KCI, 2.5 mmol/LL MgCI2, 0.45% Nonidet P-40, 0.45% Tween 20, 0.01%% gelatin) containing 5% Chelex resin (Chelex 100; Bio-Radd Laboratories, Hercules, CA) and 3 to 5 /il of Proteinase-KK (10 mg/ml) at C followed by a 10-minute incubationn at C to inactivate Proteinase-K.
MicrosatelliteMicrosatellite Analysis
Microsatellitee analysis was performed by PCR with 21 microsatellitee primer pairs. Markers were selected either becausee of their location at tumor suppressor loci known too be involved in gastric carcinogenesis, near (or in) geness involved in syndromes that contain gastric cancer inn their phenotype or because of their inclusion in marker panelss used for the determination of MSI. The markers usedd are listed in 
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Onee of the primers of each marker was fluorescently labeled.. Optimal MgCI2 and dNTP concentrations were obtainedd for each primer pair at an annealing temperaturee of C using control human DNA. PCR was performedd in a PTC-100 thermal cycler (MJ Research, Inc., Waltham,, MA) during 40 cycles in a total reaction volume off 20 (Lil, containing 40 ng of each primer, 0.1 mg/ml bovinee serum albumin, and 1.0 U of Platinum Taq (Life Technologies,, Inc., Rockville, MD) in the buffer supplied byy the manufacturer. The PCR products were analyzed usingg an automated ABI 377 sequencer and Genescan 2.11 software (PE Biosystems, Foster City, CA).
ScoringScoring of LOH and MSI
Normall samples with two distinctly sized alleles at a particularr marker were called "informative." For all informativee markers the allelic imbalance factor was calculatedd essentially as described by Cawkwell and colleagues. 200 A tumor was considered to show LOH at a particularr marker if the allelic imbalance factor was >1.6 orr <0.63. A finding of LOH had to be confirmed at least onceonce to ensure reproducibility. For each individual the fractionall allelic loss (FAL) was calculated as the ratio of LOH-positivee markers to the total number of informative markerss of that case. The FAL value therefore served as ann overall measure of genetic instability at the tested loci.
Casess with an additional peak in the tumor DNA comparedd with their respective normal sample were scored ass "microsatellite instable" (MSI) for a given marker. Tumorss that exhibited MSI or that showed inconsistent resultss in repeated experiments at a given locus were excludedd for analysis of LOH at that locus. With respect to MSI,, tumors were classified according to international criteria. 211 Tumors were scored as stable (MSS) when no shiftss were observed, as MSI-low (MSI-L) when shifts weree seen in <40% of the markers and as MSI-high (MSI-H)) with instability in ==40% of the markers. MSI had too be confirmed at least once, to ensure reproducibility.
Immunohistochemistry Immunohistochemistry
Immunohistochemistryy for p53 and DPC4 was performed usingg the monoclonal antibodies DO-7 (DAKO) and clone B88 (Santa Cruz Biotechnology Inc., Santa Cruz, CA), respectively.. Briefly, paraffin-embedded specimens were sectionedd (5 /im), deparaffinized, and heat treated in 0.011 mol/L of Na-citrate buffer (pH 6.0) for 10 minutes in aa Prestige Medical Series 2100 clinical autoclave (Prestigee Medical, Blackburn, UK). Subsequently the slides weree immersed in 0.3% hydrogen peroxide in methanol forr 30 minutes. Nonspecific binding sites were blocked in 5%% normal goat serum/phosphate-buffered saline (PBS) forr 1 hour at room temperature after which the slides were incubatedd with the respective primary antibody in 5% normall goat serum/PBS for 1 hour. The Ultravision antipolyvalentt HRP detection system (Lab Vision Corp., Fremont,, CA) was used to visualize antibody-binding sites withh 3,3'-diaminobenzidine as a chromogen. Sections weree counterstained with hematoxylin.
p533 immunoreactivity was scored as negative, weak (withh weak to moderate staining in <30% of the tumor cells),, or positive (with moderate to strong staining in >30%% of the tumor cells). DPC4/SMAD4 immunoreactivityy was scored as either negative or positive. 
StatisticalStatistical Analysis
Forr statistical analysis the Fisher exact test, and the Mann-Whitneyy U-test were used where indicated. A twosidedd P value <0.05 was considered statistically significant. .
Results Results
AA total of 57 tumors was studied for the presence of HP andd EBV and molecular alterations using polymorphic microsatellitee markers and immunohistochemistry. The overalll frequency of LOH markers as indicated by the meann FAL value was 0 278 for the complete study group. Representativee examples of LOH are shown in Figure 1 . Markerss that showed relatively frequent LOH (>30%) weree on chromosomal arms 3p (31%), 9p (37%), 17p (40%),, 18q (42%), and 19p (48%).
Off all 57 tumors, 15 tumors (26%) were positive for EBV ass tested by EBER RNA in situ hybridization. Patients with EBV-positivee tumors were predominantly male and on averagee 5.7 years younger when compared to patients withh EBV-negative tumors. Other baseline characteristics weree not significantly different between these two groups (Tablee 2). A frequency distribution of allelic loss accordingg to EBV status at the chromosomal arms tested is depictedd in Figure 2 . There was a significant inverse relationshipp between positivity for EBV and the mean FAL valuee (Table 3) too EBV status a significant inverse association was found betweenn EBV-positivity and LOH at chromosomal arms 5qq (APC), 17p (TP53), and 18q (DPC4/SMAD4) ( Table 4 ; typicall results are shown in Figure 3 ). Usingg immunohistochemistry, we analyzed the tumors forr positivity for p53 (17p) and DPC4/SMAD4 (18q). Immunohistochemistryy for p53 was evaluated in 54 carci- nomass and 33 cases were scored positive (61%). Unequivocall positivity, defined as moderate to strong positivityy in more than 30% of the carcinoma cells, was observedd in 16 cases (29%). None of the EBV-positive carcinomass were scored positive for p53 immunoreactivityy in contrast to 39% of the EBV-negative carcinomas (Figuree 3, Table 5 ). Loss of DPC4/SMAD4 expression was observedd in eight cases (15%). No association was found betweenn EBV positivity and loss of DPC4/SMAD4 expression.. In addition, no association was found between EBV positivityy and MSI (Table 3) . MSI was found in 17 tumors (30%),, 6 of which showed MSI-H and 11 of which were MSI-L L Off the 57 tumors analyzed, 18 tumors (32%) were positivee for HP, as tested by histopathological evaluation andd immunohistochemistry of the tissue sections. There wass no association between HP positivity and mean FAL valuee (Table 3) . HP status was neither significantly associatedd with LOH at specific markers nor with MSI (Table 3) .
Discussion Discussion
Inn the present study we compared the prevalence of LOH att several tumor suppressor loci and MSI in 57 gastric carcinomass using 21 polymorphic microsatellite markers. Thee LOH data for the total number of carcinomas were comparablee to those reported in other allelotype studies off gastric cancer.
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Thee overall prevalence of LOH at the tested loci, as measuredd by the mean FAL value, was not associated withh HP status. In addition HP status was not significantly associatedd with any specific molecular changes, includingg MSI, which is in line with several previous reports on HPP and molecular alterations. 22, 23 Inn contrast, a significantly lower FAL value appeared to bee associated with the presence of EBV in the carcinoma cells,, as tested by in situ hybridization for EBER1 nuclear RNAA transcripts. The pattern of LOH was also different in thee EBV-positive and EBV-negative tumors. These results stronglyy suggest that EBV-positive gastric carcinomas followw a different pathogenetic pathway, at least on the geneticc level, a notion that is in line with recent reports on EBV-positivee gastric carcinomas.
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LOHH is thought to contribute to tumor suppressor gene inactivation.. Methylation is currently regarded as an alternativee mechanism for silencing tumor suppressor genes.. In a recent publication more CpG islands were foundd to be methylated in EBV-positive gastric cancers whenn compared with cancers negative for EBV.
12 It wouldd be conceivable that the lower FAL in the present studyy among the EBV-positive cancers might be compensatedd for by a higher frequency of gene inactivation throughh promotor hypermethylation. Frequent targets of hypermethylationn are p16 on chromosomal arm 9p, STK11/LKB1STK11/LKB1 on 19p, and the mismatch repair genes. 
No.. of LOH/intormative e cases s 1/7 7 1/8 8 0/9 9 1/12 2 0/12 2 0/12 2 0/15 5 1/10 0 2/12 2 2/14 4 0/11 1 1/9 9 0/9 9 0/6 6 0/10 0 0/10 0 2/10 0 1/11 1 2/-1 1 3/14 4 3/7 7 1/9 9 4/11 1 1/9 9 mechanismm for tumor suppressor gene inactivation, couldd explain the current observations. Also,, LOH was measured at a limited number of specificc loci, and it may not be legitimate to generalize this findingg and to conclude that EBV infection is accompaniedd by a genome-wide reduction in genetic instability. Thee microsatellite markers in this study were chosen basedd on the reported frequency of LOH at their respectivee loci in gastric cancer in general and EBV-positive carcinomass comprise only a minority (~8 to 10%) of conventionall gastric adenocarcinomas. Therefore, these resultss may reflect the fact that the LOH markers were in somee way selected for EBV negativity of the tumors Whenn LOH at specific markers was assessed, a strong inversee correlation was seen between EBV positivity and LOHH at specific markers at chromosomal arms 5q, 17p, andd 18q. Particularly, the inverse relation between EBV andd LOH at chromosomal arm 17p suggests a difference withh regard to the p53 tumor suppressor pathway. For example,, it has been reported that the EBV-encoded EBNA-55 protein {alternatively designed EBNA-LP) can formm a molecular complex in vitro with both the p53 and retinoblastomaa (RB) proteins. 27 It is conceivable that bindingg with EBNA-5 may lead to an accelerated degradationn of either one or both of these tumor suppressor proteins.. This would imply a mechanism sharing analogy too that reported for the E6 and E7 proteins of certain humann papillomaviruses in the pathogenesis of squamouss cell carcinoma of the cervix, resulting in an abrogatedd tumor suppressor pathway without the need of geneticc alteration of the involved gene itself. In line with this,, immunohistochemical analysis for p53 protein revealedd an inverse correlation of EBV positivity and p53 positivity. .
Itt is more difficult to speculate about the possible mechanismss that are involved in the observed negative associationn between EBV positivity and LOH at 5q and 18q.. Putative targets of LOH on these chromosomal arms mayy be APC on 5q and DCC, DPC4/SMAD4. or JV18 on 18q.. However, there is little evidence for interaction of anyy of these tumor suppressor gene products and EBV.
LOHH at chromosomal arm 18q21, the location of the DPC4/SMAD4DPC4/SMAD4 tumor suppressor gene was observed frequently.. Inactivation of this gene at the genetic level is stronglyy correlated to loss of expression of DPC4/SMAD4 proteinn in pancreatic cancer 2B We observed loss of expressionn of DPC4/SMAD4 protein in only 15% of all gastricc carcinomas examined and this was not correlated withh LOH at 18q21. Furthermore, genetic inactivation of OPC4/SMAD4OPC4/SMAD4 is rare in gastric carcinomas, 29 suggesting thatt DPC4/SMAD4 is not the target of LOH at this locus In vieww of the above, also hypermethylation as a potential phenomenonn that could explain the observed differences inn LOH at 5q, 17p, and 18 is unlikely.
Inn a previous study using comparative genomic hybridization,, no association was found between DNA ploidyy and the EBV status and also loss of chromosomal armm 17p was not different. 25 These somewhat contradictoryy results are not easily explained. Differences in study materialss and technicalities because of different methodologyy provide the most likely explanation. In general, allelicc loss measured by specific microsatellite markers willl be considered more sensitive and provide more accuratee results.
Thee role of EBV in carcinogenesis of the stomach is not completelyy understood. The latency type of EBV in gastricc adenocarcinomas is distinct from the known EBV latencyy types, eg, in Burkitt's lymphomas and nasopharyngeall carcinomas.
910 This is mainly because of the expressionn of the latent membrane protein 2A (LMP2A) andd the absence of LMP1 in gastric adenocarcinomas. Thee transforming BARF1 gene is frequently expressed in EBV-positivee gastric carcinomas.
10 Sharing homology withh the cellular proto-oncogene c-fms, BARF1 may providee an alternative way for the pathogenesis of EBVassociatedd epithelial cancers, ie, gastric adenocarcinomaa and nasopharyngeal carcinoma, independent of LMP-11 expression. In this manner, EBV could provide a surrogatee for further accumulation of genetic instability oncee the cells are infected and this may also explain our findingss in EBV-positive tumors.
Ann alternative explanation for our results could be that susceptibilityy for EBV infection is determined by a specificc molecular genetic route that involves other genetic changess than those reported frequently for conventional gastricc carcinomas. This would be in line with our unpublishedd observations (Zur Hausen and colleagues, submitted)) that EBV infection occurs most likely at a relatively latee stage of carcinogenesis in the stomach, ie, at the transitionn of high-grade dysplasia into invasive carcinoma,, EBV positivity would then rather be a consequencee of the different molecular pathway.
Inn conclusion, EBV-positive carcinomas should be regardedd as a separate entity with a distinct pathogenesis att the molecular level, when compared to EBV-negative carcinomas.. Whether EBV positivity is a cause or merely aa consequence of this difference remains to be elucidated.. Likewise, the exact mechanism of a possible oncogenicc role of EBV in gastric epithelial cells needs furtherr study.
